scholarly journals Drug-Induced Autoimmune Hemolytic Anemia in a 78-Year-Old African-American Man with Chronic Lymphocytic Leukemia

2014 ◽  
Vol 45 (3) ◽  
pp. e105-e108
Author(s):  
Alex Sartori ◽  
Brian Staley ◽  
Angela Skipper
Keyword(s):  
African American ◽  
Chronic Lymphocytic Leukemia ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Lymphocytic Leukemia ◽  
Drug Induced

Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia

1996 ◽  
Vol 38 (4) ◽  
pp. 359-360 ◽  
Author(s):  
G. Tertian ◽  
J. Cartron ◽  
C. Bayle ◽  
A. Rudent ◽  
T. Lambert ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Lymphocytic Leukemia

Kaposi sarcoma following autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia

2018 ◽  
Vol 12 (1) ◽  
pp. 99-102 ◽  
Author(s):  
Utku Iltar ◽  
Vedat Aslan ◽  
Mesut Gocer ◽  
Fatma Aykac ◽  
İlknur Nizam ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Kaposi Sarcoma ◽  
Lymphocytic Leukemia

scholarly journals Autoimmune Hemolytic Anemia After Relapse of Chronic Myeloid Leukemia: A Case Report

2019 ◽  
Vol 12 ◽  
pp. 1179545X1989457
Author(s):  
Tahseen Hamamyh ◽  
Mohamed A Yassin
Keyword(s):  
Case Report ◽  
Chronic Myeloid Leukemia ◽  
Chronic Lymphocytic Leukemia ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia ◽  
Sudden Drop ◽  
Leukemia Relapse

Autoimmune hemolytic anemia is one of the differential diagnoses for anemia in patients with lymphoproliferative neoplasia, such as chronic lymphocytic leukemia, who experience sudden drop in hemoglobin. The association between autoimmune hemolytic anemia and chronic myeloid leukemia on the contrary is unusual. Here we present a patient with a background of chronic myeloid leukemia treated previously with Tyrosine Kinase Inhibitors, then developed autoimmune hemolysis simultaneously with chronic myeloid leukemia relapse. Hemolysis was treated with steroids with good response.

Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features

Blood ◽  
2000 ◽  
Vol 95 (9) ◽  
pp. 2786-2792 ◽  
Author(s):  
Francesca R. Mauro ◽  
Robert Foa ◽  
Raffaella Cerretti ◽  
Diana Giannarelli ◽  
Serelina Coluzzi ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Hemolytic Anemia ◽  
Survival Probability ◽  
Autoimmune Hemolytic Anemia ◽  
Immunosuppressive Agents ◽  
Rare Event ◽  
Lymphocytic Leukemia ◽  
Independent Effect ◽  
Complete Disappearance ◽  
Prognostic Features

Fifty-two cases of autoimmune hemolytic anemia (AHA) were observed within a series of 1203 patients (4.3%) with chronic lymphocytic leukemia (CLL) followed at a single institution. Nineteen were observed at the time of CLL diagnosis and 33 during the clinical follow-up. Ninety percent of the patients with CLL/AHA showed active CLL and 25% had been treated previously. The antierythrocyte autoantibody (AeAb) was an IgG in 87% of cases and an IgM in 13%. A lymphocyte count more than 60 × 109/L (P < .00001), age above 65 years (P < .01), and male gender (P < .01) emerged as independent parameters that correlated significantly with an increased rate of AHA at CLL diagnosis. Patients previously treated with chlorambucil (CB) plus prednisone (PDN) and with fludarabine plus PDN showed a similar rate of AHA (1.8% and 2.5%, respectively). After steroid therapy associated with CB in case of active CLL, 70% of patients achieved the complete disappearance of the AeAb. The actuarial AHA relapse-free survival probability was 54% at 5 years and the median survival probability after AHA was 41 months. Infections represented the main cause of morbidity and mortality. IgG AHA and the occurrence of AHA at the same time of CLL diagnosis emerged as independent factors significantly correlated with a better survival probability of AHA/CLL patients. Taken together, this study indicates that in CLL, AHA is a rare event with no independent effect on survival for which steroids, associated with CB if required, and a careful management of infections may successfully control the 2 conditions. Cooperative studies are needed to better define the optimal steroid schedule and the therapeutic role of other immunosuppressive agents and splenectomy.

scholarly journals Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab

Leukemia ◽  
2007 ◽  
Vol 21 (8) ◽  
pp. 1841-1842 ◽  
Author(s):  
B Royer ◽  
I Vaida ◽  
A Etienne ◽  
R Garidi ◽  
G Damaj ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Lymphocytic Leukemia ◽  
Cell Chronic Lymphocytic Leukemia

Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia

2006 ◽  
Vol 30 (12) ◽  
pp. 1589-1590 ◽  
Author(s):  
Hiroko Nishida ◽  
Tadashi Murase ◽  
Hironori Ueno ◽  
Jae Wong Park ◽  
Takahiro Yano ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Hemolytic Anemia ◽  
Autoimmune Hemolytic Anemia ◽  
Lymphocytic Leukemia ◽  
Cell Chronic Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document